Therapy Areas: Hereditary Disorders
Synageva completes enrollment in Phase I/II study of SBC-102 for LAL Deficiency
23 December 2011 - US Synageva BioPharma Corp (NASDAQ:GEVA) said yesterday it had finalised enrollment in a Phase I/II study of enzyme replacement therapy SBC-102 for late onset Lysosomal Acid Lipase (LAL) Deficiency.

Interim data has been selected for an oral presentation at the upcoming Lysosomal Disorder Network (LDN) WORLD Symposium being held 8-10 February 2012 in San Diego, CA, Synageva added.

The Phase I/II trial was designed to assess the safety and tolerability of SBC-102 administered weekly in patients with liver dysfunction due to late onset LAL Deficiency.

The study is fully enrolled with all patients completing their scheduled infusions. There have been no treatment-related serious adverse events, infusion-related reactions or withdrawals reported to date, and patients have begun transitioning into the extension study.
Login
Username:

Password: